Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment

Inclusion criteria: * Male and female patients aged between 18 and 79 * Patients with chronic kidney disease (CKD-3) * Patients should be on stable ACE-I treatment (same type and regimen) for at least 2 months prior to screening * Body weight between 50.0 kg and 115.0 kg inclusive if male, between 40.0 kg and 100 kg inclusive if female * If female, patients must be permanently sterilized for more than 3 months or postmenopausal * Having given written informed consent prior to the study. Exclusion criteria: * Women of child bearing potential. * Uncontrolled clinically relevant cardiovascular, pulmonary, gastro-intestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female) or infectious disease, or signs of acute illness * Active hepatitis, hepatic insufficiency * Acute renal failure * Patients requiring dialysis during the study * Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. * Any history of orthostatic dysregulation (including but not limited to neurocardiogenic syncope, postural orthostatic tachycardia syndrome) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.